Mainz Biomed has launched ColoFuture, an international clinical study that will evaluate the potential integration of mRNA biomarkers into its ColoAlert colorectal cancer detection test.
Acquired by Mainz from the Université de Sherbrooke in Quebec in January, the mRNA biomarkers had been shown in prior studies to provide high sensitivity and specificity for detecting colon cancer and precancerous lesions.
The first patient has now been enrolled in ColoFuture. In the trial, researchers will evaluate the effectiveness of these biomarkers in extending ColoAlert's capability to include identification of advanced adenomas while also increasing the test's diagnostic sensitivity and specificity, Mainz said.
